NanoRepro AG (XTER:NN6) ROCE %: -4.69% (As of Jun. 2025)


XTER:NN6 NanoRepro AG XTER:NN6
63 GF Score
Price €2.08
GF Value €1.01
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is NanoRepro AG ROCE %?

NanoRepro AG XTER:NN6 63 ROCE % is -4.69% as of Jun. 2025. GuruFocus rates XTER:NN6 with a GF Score™ of 63/100 and a GF Value™ of €1.01 (Significantly Overvalued). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. NanoRepro AG's annualized ROCE % for the quarter that ended in Jun. 2025 was -4.69%.

NanoRepro AG  (XTER:NN6) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

NanoRepro AG ROCE % Related Terms

NanoRepro AG ROCE % Historical Data

* Premium members only.

The historical data trend for NanoRepro AG's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NanoRepro AG ROCE % Chart

NanoRepro AG Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 41.71 100.65 -7.49 -9.96 -8.68

NanoRepro AG Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.69 -10.61 -11.24 -6.14 -4.69
XTER:NN6
63GF Score
NanoRepro AG XTER:NN6
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NanoRepro AG ROCE % Calculation

NanoRepro AG's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=-3.45/( ( (41.458 - 0.673) + (39.025 - 0.299) )/ 2 )
=-3.45/( (40.785+38.726)/ 2 )
=-3.45/39.7555
=-8.68 %

NanoRepro AG's ROCE % of for the quarter that ended in Jun. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2025 )  (Q: Dec. 2024 )(Q: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2025 )  (Q: Dec. 2024 )(Q: Jun. 2025 )
=-1.792/( ( (39.025 - 0.299) + (37.992 - 0.314) )/ 2 )
=-1.792/( ( 38.726 + 37.678 )/ 2 )
=-1.792/38.202
=-4.69 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -4.69% mean?
NanoRepro AG (XTER:NN6) has a ROCE % of -4.69% as of Jun. 2025.
Is NanoRepro AG's ROCE % too high?
NanoRepro AG's current ROCE % is -4.69%. Overall, NanoRepro AG has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NanoRepro AG's ROCE % compare to TMO and DHR?
NanoRepro AG's ROCE % of -4.69% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Diagnostics & Research company?
A good ROCE % depends on the Medical Diagnostics & Research industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. NanoRepro AG's current ROCE % is -4.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NanoRepro AG stock overvalued right now?
Based on GuruFocus' analysis, NanoRepro AG (XTER:NN6) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.01, compared to a current price of €2.08 — trading 105.9% above its estimated fair value. The current ROCE % is -4.69%. NanoRepro AG's overall GF Score™ is 63/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For NanoRepro AG (XTER:NN6), the current ROCE % is -4.69% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NanoRepro AG (XTER:NN6) Overvalued in 2026?

Based on GuruFocus' analysis, NanoRepro AG stock appears to be overvalued. The current stock price of €2.08 is trading 105.9% above its estimated GF Value™ of €1.01. GuruFocus considers NanoRepro AG to be Significantly Overvalued.

Key valuation signals for XTER:NN6:

  • ROCE %: -4.69%
  • GF Value™: €1.01 vs. price of €2.08 (105.9% above fair value)
  • GF Score™: 63/100 with 6 warning signs

No single metric tells the full story. See the XTER:NN6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NanoRepro AG Business Description

Address Untergasse 8, Marburg, DEU, 35037
NanoRepro AG is engaged in the development, manufacturing, and distribution of CE-certified rapid diagnostic tests (self-tests) and food supplements for both, home and professional use.
63GF Score

Get the complete analysis for XTER:NN6

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.08
Price
€1.01
GF Value